Published • loading... • Updated
RQ Bio secures $115m to develop influenza antibody programme
Summary by Verdict Hospital
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Verdict HospitalReposted by 
Pharmaceutical Business review
Pharmaceutical Business reviewRQ Bio secures $115m to develop influenza antibody programme
RQ Bio has closed a $115m Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.The post RQ Bio secures $115m to develop influenza antibody programme appeared first on Hospital Management.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
